The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer

Shuangcui Wang; Guan Zhang; Qian Cui; Yanjie Yang; Dong Wang; Aqing Liu; Ying Xia; Wentao Li; Yunhe Liu; Jianchun Yu

doi:10.1002/iid3.1099

The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer

Immun Inflamm Dis. 2023 Nov;11(11):e1099. doi: 10.1002/iid3.1099.

Authors

Shuangcui Wang^{1

2

3}, Guan Zhang^{1

2

3}, Qian Cui^{1

2

3}, Yanjie Yang^{1

2

3}, Dong Wang^{1

2

3}, Aqing Liu^{1

2

3}, Ying Xia^{1

2

3}, Wentao Li¹, Yunhe Liu¹, Jianchun Yu¹

Affiliations

¹ Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
² National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
³ Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Abstract

The dendritic cell (DC)-T cell axis is a bridge that connects innate and adaptive immunities. The initial immune response against tumors is mainly induced by mature antigen-presenting DCs. Enhancing the crosstalk between DCs and T cells may be an effective approach to improve the immune response to non-small cell lung cancer (NSCLC). In this article, a review was made of the interaction between DCs and T cells in the treatment of NSCLC and how this interaction affects the treatment outcome.

Keywords: DCs; NSCLC; T cells; artificial DCs; chimeric antigen receptor T cell immunotherapy.

Publication types

Review

MeSH terms

Adaptive Immunity
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
T-Lymphocytes